Plaque subcommittee tones down dose-response requirement in "points to consider" draft.
This article was originally published in The Rose Sheet
Executive Summary
PLAQUE SUBCOMMITTEE RELAXES DOSE-RESPONSE STUDY REQUIREMENT in the draft "points to consider" section of the OTC plaque panel report during an Aug. 14 meeting. The OTC Plaque Products Subcommittee's discussion focused on several changes to the draft "points to consider" document proposed by the Nonprescription Drug Manufacturers Association and the Cosmetic, Toiletry, and Fragrance Association in a July 31 submission.